In a recent study published in the journal Nature Medicine, an international team of researchers evaluated the efficacy, safety, and tolerability of extended-release ketamine tablets (R-107) in adult ...

AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) announces the launch of ...

Adjusted EBITDA was $ (0.8) million for the second quarter of fiscal 2026 compared to $1.3 million in the year ago period. The change primarily relates to the increased EXXUA launch investments and ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...

Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder leading to impairments in learning and behaviour. ADHD affects approx. 3-5% of adults and 5-9% of children and ...

(RTTNews) - Amneal Pharmaceuticals (AMRX) announced it has received FDA approval of its New Drug Application for Pyridostigmine Bromide Extended-Release Tablets USP 105 mg. PB ER 105 mg tablets are a ...

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening condition ...

Onyda XR should not be substituted for other clonidine products on a mg-per-mg basis. The Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride) extended-release oral ...

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...